Actively Recruiting
Global Phase III Trial Evaluating Lisaftoclax Plus Acalabrutinib Compared to Immunochemotherapy in Newly Diagnosed CLLSLL Patients
Led by Ascentage Pharma Group Inc. · Updated on 2026-07-28
344
Participants Needed
10
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of Lisaftoclax APG-2575 and Acalabrutinib compared to immunochemotherapy for patients newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma CLLSLL. This global, multicenter, Phase III study aims to confirm the efficacy and safety of this combination treatment in patients who meet specific clinical criteria, including measurable disease and an ECOG score between 0 and 2. Participants will be randomly assigned to receive either the investigational treatment of Lisaftoclax 600 mg daily plus Acalabrutinib 100 mg twice daily for up to 18 treatment cycles or one of two immunochemotherapy regimens involving drugs such as fludarabine, cyclophosphamide, rituximab, or chlorambucil over six cycles. Both treatments are administered mostly by oral or intravenous routes following fixed dosing schedules. Throughout the study, participants will undergo regular assessments to monitor progression-free survival, response rates, minimal residual disease negativity, and safety over one year. Evaluations include physical exams, laboratory tests, and adverse event monitoring. Participants must be able to consent, complete study procedures, and will be followed for treatment outcomes and safety, with the trial expected to complete by August 2028.
CONDITIONS
Brief Title
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Research Team
M
Miguel Rosado-Cadena, MD
J
Jocelyn Budzynski
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here